Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Cancer Cell

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 12620411
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The roles of FLT3 in hematopoiesis and leukemia.

  2002cited by this paper
• The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts.

  2002cited by this paper
• CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

  2002cited by this paper
• Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.

  2002cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• MLL–ENL cooperates with SCF to transform primary avian multipotent cells

  2002cited by this paper
• A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.

  2002cited by this paper
• Prediction of central nervous system embryonal tumour outcome based on gene expression

  2002cited by this paper
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002cited by this paper
• Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

  2002cited by this paper
• Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain

  2002cited by this paper
• MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia

  2002cited by this paper
• Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.

  2002cited by this paper
• SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.

  2002cited by this paper
• Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

  2002cited by this paper
• Gene expression correlates of clinical prostate cancer behavior.

  2002cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

  2001cited by this paper
• Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

  2001cited by this paper
• Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

  2001cited by this paper
• KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.

  2001cited by this paper
• Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

  2000cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• Tandem duplication of the FLT3 gene is infrequent in infant acute leukemia

  2000cited by this paper
• Sensitivity of FISH in detection of MLL translocations

  2000cited by this paper
• Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.

  2000cited by this paper
• PLAG1 fusion oncogenes in lipoblastoma.

  2000cited by this paper
• The critical role of chromosome translocations in human leukemias.

  1998cited by this paper
• Intensified therapy for infants with acute lymphoblastic leukemia

  1997cited by this paper
• Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.

  1996cited by this paper
• Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors.

  1995cited by this paper
• Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines.

  1995cited by this paper
• BCL‐2 expression by leukaemic blasts in a SCID mouse model of biphenotypic leukaemia associated with the t(4;ll)(q21;q23) translocation

  1995cited by this paper
• Expression of the FLT3 gene in human leukemia-lymphoma cell lines.

  1994cited by this paper
• Versatile retroviral vectors for potential use in gene therapy.

  1994cited by this paper
• The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin‐7

  1994cited by this paper
• STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells.

  1994cited by this paper
• Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells.

  1993cited by this paper
• Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome.

  1993cited by this paper
• Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia.

  1992cited by this paper
• A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations.

  1991cited by this paper
• Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family.

  1991cited by this paper
• Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases.

  1991cited by this paper
• Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia.

  1990cited by this paper
• Establishment of a leukemic cell model for studying human pre-B to B cell differentiation.

  1989cited by this paper
• erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

  1987cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics.

  1985cited by this paper

• Phenocopies in acute lymphoblastic leukemia: Redefining leukemia subtypes in the transcriptomic era

  2026cites this paper
• Characterization of the mutational landscapes in Japanese patients with early-onset colorectal cancer from comprehensive genomic profiling data

  2025cites this paper
• Regulation of H3K4me3 breadth and MYC expression by the SETD1B catalytic domain in MLL-rearranged leukemia

  2025cites this paper
• Infant acute lymphoblastic leukaemia—Progress from worldwide clinical efforts

  2025cites this paper
• Marine-Derived Bisindoles for Potent Selective Cancer Drug Discovery and Development

  2024cites this paper
• Cytotoxicity of Doxorubicin-Curcumin Nanoparticles Conjugated with Two Different Peptides (CKR and EVQ) against FLT3 Protein in Leukemic Stem Cells

  2024cites this paper
• KMT2A-rearranged acute lymphoblastic leukaemia

  2024cites this paper
• Prevalence of FLT3 gene mutation and its expression in Brazilian pediatric B-ALL patients: clinical implications

  2024cites this paper
• Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children’s Oncology Group trial AALL15P1

  2024cites this paper
• Landscape of FLT3 Variations Associated with Structural and Functional Impact on Acute Myeloid Leukemia: A Computational Study

  2024cites this paper
• CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in KMT2A-Rearranged Acute Lymphoblastic Leukemia

  2023cites this paper
• Case Report: Rare IKZF1 Gene Fusions Identified in Neonate with Congenital KMT2A-Rearranged Acute Lymphoblastic Leukemia

  2023cites this paper
• Combination fedratinib and venetoclax has activity against human B-ALL with high FLT3 expression

  2023cites this paper
• Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia

  2023cites this paper
• Activated Src kinases downstream of BCR-ABL and Flt3 induces proteasomal degradation of SHIP1 by phosphorylation of tyrosine 1021.

  2023cites this paper
• Systematic characterization of the HOXA9 downstream targets in MLL-r leukemia by noncoding CRISPR screens

  2023cites this paper
• Recent developments in the Medicinal Chemistry and therapeutic potential of anti-cancer Protacs based molecules.

  2022cites this paper
• Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia

  2022cites this paper
• Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia

  2021cites this paper
• Acute lymphoid leukemia etiopathogenesis

  2021cites this paper
• CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents

  2021cites this paper
• Irinotecan Induces Disease Remission in Xenograft Mouse Models of Pediatric MLL-Rearranged Acute Lymphoblastic Leukemia

  2021cites this paper
• Neonatal Leukemia.

  2021cites this paper
• Expression of a novel type of KMT2A/EPS15 fusion transcript in FLT3 mutation-positive B-lymphoblastic leukemia with t(1;11)(p32;q23).

  2021cites this paper
• Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell Survival

  2021cites this paper
• The effect of co-treatments of chemotherapeutic drugs and curcumin on cytotoxicity and FLT3 protein expression in leukemic stem cells

  2021cites this paper
• FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631

  2021cites this paper
• Co-Treatments of Edible Curcumin from Turmeric Rhizomes and Chemotherapeutic Drugs on Cytotoxicity and FLT3 Protein Expression in Leukemic Stem Cells

  2021cites this paper
• Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-risk Leukemias: A Report from the LEAP Consortium.

  2021influential citation
• IDENTIFICATION OF MOLECULAR ALTERATIONS IN VENEZUELAN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA DIAGNOSIS

  2020cites this paper
• Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML with activating FLT3 mutations.

  2020cites this paper
• Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia

  2020cites this paper
• FMS‐like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer

  2020cites this paper
• Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia

  2020cites this paper
• Evaluation of ERK as a therapeutic target in acute myelogenous leukemia

  2019cites this paper
• Disruption of the menin-MLL interaction triggers menin protein degradation via ubiquitin-proteasome pathway.

  2019cites this paper
• Targeting PRMT1-Mediated FLT3 Methylation Disrupts Maintenance of MLL- rearranged Acute Lymphoblastic Leukemia.

  2019cites this paper
• FLT3 overexpression in acute leukaemias: New insights into the search for molecular mechanisms.

  2019cites this paper
• Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.

  2019cites this paper
• The Impact of the Cellular Origin in Acute Myeloid Leukemia: Learning From Mouse Models

  2019cites this paper
• Molecular landscape in adult acute myeloid leukemia: where we are where we going?

  2019cites this paper
• FLT3 inhibitor quizartinib (AC220)

  2019cites this paper
• The RS4;11 cell line as a model for leukaemia with t(4;11)(q21;q23): Revised characterisation of cytogenetic features

  2019cites this paper
• How I treat infant leukemia.

  2019cites this paper
• Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation

  2019cites this paper
• Современные представления о терапии острого лейкоза у детей до 1 года

  2019cites this paper
• Genetically engineered CAR NK cells display selective cytotoxicity against FLT3‐positive B‐ALL and inhibit in vivo leukemia growth

  2019cites this paper
• Estudi del perfil d'expressió de les histones deacetilasa (hdac) en pacients pediàtrics amb leucèmia aguda

  2018cites this paper
• MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin

  2018cites this paper
• Identification of genes associated with cancer progression and prognosis in lung adenocarcinoma: Analyses based on microarray from Oncomine and The Cancer Genome Atlas databases

  2018cites this paper
• Targeted therapy for fusion-driven high-risk acute leukemia.

  2018cites this paper
• Epigenetic Modulators

  2018cites this paper
• How I Treat How I treat infant leukemia

  2018cites this paper
• Proteína multifuncional ADE2 como nexo entre vías de recuperación y síntesis de novo de nucleótidos

  2018cites this paper
• ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia

  2018cites this paper
• Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications.

  2018cites this paper
• A phase 1/2, open‐label, dose‐escalation study of midostaurin in children with relapsed or refractory acute leukaemia

  2018cites this paper
• Cancer II

  2018cites this paper
• Genomics of Acute Myeloid Leukemia

  2017cites this paper
• Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase

  2017cites this paper
• Pathway Enrichment Analysis with Networks

  2017cites this paper
• Flow cytometric characterization of acute leukemia reveals a distinctive “blast gate” of murine T-lymphoblastic leukemia/lymphoma

  2017cites this paper
• Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.

  2017cites this paper
• Inhibition of USP10 induces degradation of oncogenic FLT3.

  2017cites this paper
• RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia.

  2017cites this paper
• Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition

  2017cites this paper
• WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

  2017cites this paper
• MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches

  2017cites this paper
• Caracterització de les alteracions moleculars de FLT3 en pacients pediàtrics afectes de leucèmia aguda. Correlació amb l’activitat i expressió dels transportadors de fàrmacs derivats de nucleòsids

  2017cites this paper
• The Biology, Prognostic Relevance, and Targeted Treatment of Ras Pathway–Positive Childhood Acute Lymphoblastic Leukemia

  2017cites this paper
• Development and identification of Set transgenic mice

  2017cites this paper
• Advances in understanding the pathogenesis of CNS acute lymphoblastic leukaemia and potential for therapy

  2017cites this paper
• The role of constitutive activation of FMS-related tyrosine kinase-3 and NRas/KRas mutational status in infants with KMT2A-rearranged acute lymphoblastic leukemia

  2017cites this paper
• Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

  2017influential citation
• Kinase Inhibitor Screening in Myeloid Malignancies.

  2017cites this paper
• Novel Aspects in Acute Lymphoblastic Leukemia 166 2 . CXCR 4 inhibitors

  2017cites this paper
• Mining Datasets for Molecular Subtyping in Cancer

  2016cites this paper
• Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics

  2016cites this paper
• BCL6 enables Ph + acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition

  2016cites this paper
• FMS-like tyrosine kinase 3 (FLT3) inhibitors: Molecular docking and experimental studies.

  2016cites this paper
• MISTRG extends PDX modeling to favorable AMLs.

  2016cites this paper
• Continuous molecular remission and regression of side effects after discontinuation of salvage therapy with sorafenib and donor lymphocyte infusions in a young patient with relapsed AML

  2016cites this paper
• Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles.

  2016cites this paper
• Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis

  2016cites this paper
• Búsqueda de fármacos para dianas terapéuticas en leucemia

  2016cites this paper
• Two cases of in-frame deletion mutation in juxtamembrane domain of the FLT3

  2016cites this paper
• A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

  2016cites this paper
• miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia

  2016cites this paper
• Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor.

  2016cites this paper
• Molecular origin of childhood acute lymphoblastic leukemia

  2016cites this paper
• FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia

  2016cites this paper
• Molecular basis and clinical significance of genetic aberrations in B-cell precursor acute lymphoblastic leukemia.

  2015cites this paper
• Cellular and Molecular Basis of KMT2A/MLL Leukaemias: From Transformation Mechanisms to Novel Therapeutic Strategies

  2015cites this paper
• TALENs-mediated gene disruption of FLT3 in leukemia cells: Using genome-editing approach for exploring the molecular basis of gene abnormality

  2015cites this paper
• Synthesis and activities of new indolopyrrolobenzodiazepine derivatives toward acute myeloid leukemia cells.

  2015cites this paper
• A role of FLT 3 gene mutation in acute myeloid leukemia patients from Pakistan

  2015cites this paper
• Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

  2015cites this paper
• Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia.

  2015cites this paper
• FLT3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical Significance

  2014cites this paper
• A Genetically Engineered Mouse Model of Neuroblastoma Driven by Mutated ALK and MYCN

  2014cites this paper